Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K; also known as calmodulin-dependent protein kinase III) has both active and inactive phosphorylation sites. An intracellular energy sensor, AMP-activated protein kinase (AMPK) was reported to activate eEF2K via increasing dephosphorylation at Ser366 (inactive site). Activated eEF2K phosphorylates and inactivates a specific substrate, eEF2, which results in the inhibition of protein translation consuming high energy. Glucose depletion (GD) is one of the primary causes for cardiomyocyte death in the developed cardiac hypertrophy. We have recently found that the expression and dephosphorylation of eEF2K (Ser366) and eEF2 phosphorylation were significantly increased in left ventricle of several cardiac hypertrophy models. However, it is almost unknown whether eEF2K/eEF2 signals affect GD-induced cardiomyocyte death. The aim of this study was to explore it. GD was induced by incubating H9c2 cells in a glucose-free medium. H9c2 cell viability, apoptotic-like nuclear condensation or protein expression was examined using a cell counting assay, DAPI staining or Western blotting, respectively. GD induced H9c2 cell death (p<0.01, n=6) and caspase-3 fragmentation (p<0.05, n=10-12). In addition, GD significantly increased phosphorylation of AMPK (p<0.05, n=6-8) and eEF2 (p<0.01, n=4-8) as well as eEF2K dephosphorylation at Ser366 (p<0.01, n=4-8). eEF2K gene knockdown (eEF2K KD) by siRNA transfection significantly increased GD-induced H9c2 cell death (p<0.05, n=7) and caspase-3 fragmentation (p<0.01, n=9). Moreover, eEF2K KD significantly facilitated GD-induced increase of nuclear condensation (44.0±3.3%, eEF2K siRNA vs. 30.9±2.4%, control siRNA p<0.01, n=5). AMPK KD did not affect GD-induced H9c2 cell death and eEF2K dephosphorylation. In conclusion, we for the first time revealed in H9c2 cells that activated eEF2K might play protective roles in GD-induced apoptosis via the inhibition of caspase-3 fragmentation, whereas AMPK activation is not directly related to the regulation of eEF2K/eEF2 signals in GD condition. The present results suggest eEF2K as a novel pharmacotherapeutic target for cardiac dysfunction.
A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death
